Development of Fluoroquinolones as First-line Drugs for Tuberculosis—at Long Last!
- 1 December 2003
- journal article
- Published by American Thoracic Society in American Journal of Respiratory and Critical Care Medicine
- Vol. 168 (11) , 1266-1268
- https://doi.org/10.1164/rccm.2309011
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of AmericaAmerican Journal of Respiratory and Critical Care Medicine, 2003
- Sterilizing Activities of Fluoroquinolones against Rifampin-Tolerant Populations of Mycobacterium tuberculosisAntimicrobial Agents and Chemotherapy, 2003
- Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trialThe Lancet, 2002
- In Vitro and In Vivo Activities of Gatifloxacin against Mycobacterium tuberculosisAntimicrobial Agents and Chemotherapy, 2002
- Effectiveness of Once-Weekly Rifapentine and Moxifloxacin Regimens against Mycobacterium tuberculosis in MiceAntimicrobial Agents and Chemotherapy, 2001
- Foreword from the Co-Editor-in-ChiefTuberculosis, 2001
- Application of fluoroquinolone pharmacodynamicsJournal of Antimicrobial Chemotherapy, 2000
- In Vitro and In Vivo Activities of Moxifloxacin and Clinafloxacin against Mycobacterium tuberculosisAntimicrobial Agents and Chemotherapy, 1998
- Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention.American Journal of Respiratory and Critical Care Medicine, 1994
- Assessment of New Sterilizing Drugs for Treating Pulmonary Tuberculosis by Culture at 2 MonthsAmerican Review of Respiratory Disease, 1993